$BIOL - EARNINGS BEAT
2021 Second Quarter Operating Highlights (all comparisons are on a year-over-year basis unless specified otherwise):
Net revenue grew 211% to $9.1 million:
Over 70% of U.S. laser sales came from new customers, continuing a positive trend
Over 35% of U.S. Waterlase sales came from dental specialists
Net revenue was 6% higher than the pre-pandemic revenues during the second quarter of 2019
Laser system sales increased 424%
Consumables and other revenue increased 173%
U.S. and international revenue increased 167% and 340%, respectively, as more dental practices were operating during the 2021 second quarter compared to the year-ago second quarter due to the COVID-19 pandemic
Gross margin was 44%, up 1,200 basis points, due to the higher year-over-year revenue, favorable revenue mix and higher average selling prices for products sold during the quarter
Net loss was $702,000 or $0.00 per share, compared to a net loss of $4.7 million or $0.12 per share a year ago
Maintained strong balance sheet, as cash and cash equivalents totaled $37.1 million at quarter end
$PSTI The force is strong with this one...
1. kENUP Foundation is currently supporting the following product developments, listed here in alphabetical order, all with the aim to reach patients during 2020:
a replication-deficient simian adenoviral vector vaccine candidate ready for rapid clinical testing.
Under development by the European-based operations of Vaccitech Limited, Oxford and the University of Oxford, with initial vaccine manufacturing anticipated to take place at facilities in the UK and Italy.
a measles vector vaccine candidate.
Under development by Themis Bioscience GmbH, Vienna, in cooperation with Institut Pasteur, Paris, with manufacturing anticipated to occur in Germany.
repurposing of Hydroxychloroquine for COVID-19 prophylaxis to protect medical staff.
Under development by Pharmakina SA, Democratic Republic of Kongo, in cooperation with the Institute for Tropical Medicine, Travel Medicine, and Human Parasitology, Prof. Dr. Peter Kremsner, of Eberhard Karls Universität Tübingen.
a therapeutic and prophylactic human monoclonal antibody candidate.
Under development by AchilleS Vaccines Srl Siena, in cooperation with the
laboratory of Dr. Rino Rappuoli, with manufacturing anticipated to occur in Italy
a RNV vaccine candidate.
Under development by Novavax Inc., and Novavax AB, Uppsala, with both antigen-manufacturing and adjuvant-manufacturing anticipated to occur in the EU.
plant-based protein production
a proprietary plant-based expression platform to mass-produce recombinant antigens and antibodies for use in diagnostics.
Under development by Cape Bio Pharms (Pty.) Ltd., Cape Town.
a cell therapy candidate for the treatment of severe pneumonia due to COVID-19.
Under development by Pluristem Ltd., Haifa, and Pluristem GmbH, Berlin.
usage of novel, recombinant BCG vaccine for the prevention of COVID-19 via the induction of trained immunity.
Under development by Serum Institute of India Pvt. Ltd., Bilthoven Biologicals B.V. and Vakzine Projekt Management GmbH (VPM), in cooperation with the Max Planck Institute for Infection Biology, Berlin.
Please dont hesitate to get back to us with any questions or comments you may have. The team can be reached at email@example.com.
Last updated on April 9, 2020 at 07:30h
$PSTI Pluristem Changes the Game with Strong Preliminary COVID-19 Results; Analyst Says ‘Buy’
TipRanks•April 8, 2020
With the war against COVID-19 waging on, Wall Street focus has locked in on the names at the frontline. Battling a formidable opponent capable of spreading without a trace, innovative technologies will be required to arm the world’s population. As such, market watchers are standing at the ready, hoping to identify the healthcare companies that can deliver effective weapons against the deadly virus.
Pluristem Therapeutics (PSTI) has a fighting chance. On April 7, the company reported its treatment for acute respiratory failure and inflammatory complications caused by COVID-19 had demonstrated robust preliminary results from the compassionate use program, sending shares 21% higher in response. Back in March, its PLX cell treatment, which uses allogeneic mesenchymal-like cells with immunomodulatory properties, got the go ahead from the Israeli Ministry of Health for use in treating severe COVID-19 patients on a per-patient basis. The therapy was designed to prevent or even reverse the harmful over-activation of the immune system.
The results have been promising to say the least. Management stated that so far, seven patients in the ICU with Acute Respiratory Distress Syndrome (ARDS) have been treated. All of the patients are alive, meaning that the survival rate is 100%, and six out of seven have progressed through at least one week of follow-up. On top of this, four patients saw respiratory parameters improve, one remained stable and only one demonstrated deterioration. Three are also in the advanced stages of being taken off ventilators.
Weighing in for H.C. Wainwright, analyst Swayampakula Ramakanth calls the early data “encouraging” and thinks the treatment could drive substantial gains for PSTI, with the next step being a regulated and multinational clinical study.
“In our view, with the ongoing pandemic affecting nearly every country and stressing healthcare systems around the world, new, effective treatments are urgently needed. Therefore, we believe that both the FDA and the EMA may expedite the approval for clinical studies and simply the regulatory paths going forward. With regulatory expediency and patients only needing a 28-day follow-up, we believe the company could complete the initial studies and report results in 2H20,” Ramakanth explained.
In line with this optimistic take, Ramakanth left a Buy rating on the stock. At $15.50, the price target puts the upside potential at a whopping 277%. (To watch Ramakanth’s track record, click here)
As for other analyst activity, it has been relatively quiet when it comes to PSTI. Only one other call has been issued recently, but it was also bullish, so the analyst consensus is a Moderate Buy. The $11.75 average price target is less aggressive than Ramakanth’s and implies 173% upside potential. (See Pluristem stock analysis on TipRanks)
BXRX =MC $52 M --FDA Decision in Q1 for a BIG Drug -- unknown low float stock =500%++ UPSIDE .LIFETIME OPP
Janney starts Baudax Bio at buy; fair value estimate $12
Baudax’s key product is Anjeso, a long-acting intravenous formulation of meloxicam, an established non-opioid pain reliever, available through an oral formulation. “We see a high probability of FDA approval in the first quarter of 2020, which would be a meaningful catalyst to drive the stock towards our fair value,” writes analyst Ester Hong.
She estimates peak U.S. sales of $355-million for Anjeso but sees “upside from increased demand for a potent non-opioid that allows patients to recover and go home faster.”
$MGI- on fire possible buyout
MKGI - Monaker Group Acquires Key Inventory and Travel Services from IDS Technology for $5.5 Million
WESTON, FL – August 22, 2019 – Monaker Group, Inc. (Nasdaq: MKGI), a technology leader in the travel and vacation rental markets, today announced it has completed an asset purchase with leading travel technology provider, IDS Technology to enhance its Monaker Booking Engine (MBE) and nexttrip.biz platform, adding new capabilities and an additional 500,000 properties in North America.
The terms of the agreement include the purchase by Monaker of key assets and technology - from IDS - along with software development and integration services for a total of $5.5 million. The consideration payable to IDS is $634,000 in cash and 1,968,000 restricted shares of Monaker’s common stock valued at $2.50 per share.
“This technology acquisition and transaction with IDS creates an opportunity to dramatically enhance our travel technology platform and accelerate our transaction growth,” said Monaker CEO, Bill Kerby. “The IDS assets will also help us to further strengthen our nexttrip.biz business travel solution with a broader selection of vacation rentals suitable for corporate travel, and are expected to capture higher margin revenue streams.”
Mr. Kerby noted that, with IDS accepting mostly restricted equity in this transaction and at an above-market valuation, “It is an indication of their confidence in Monaker’s ability to enhance shareholder value, and to be a true partner in this endeavor. It also validates the power of Monaker’s existing MBE and nexttrip.biz platforms and their greater potential.”
The purchased assets and services include:
API software development to provide for instant-booking access to more than 500,000 North American vacation rental properties. This access will more fully round out Monaker’s existing vacation rental inventory which has been located primarily in Europe and Asia. Additional Alternative Lodging Rental (ALR) products, commonly referred to as vacation rentals, will also be added, including wholesale access to exclusive high-value offerings.
Exclusive ownership of IDS booking engine software technology for air, car, and hotel reservations, including proprietary API connections to travel providers and distributors. This will make MBE a more complete B2B solution for the simultaneous booking of air, car and hotel, rather than relying upon integration with existing client booking systems. It will enable MBE and nexttrip.biz to capture new revenue streams from the booking of air, car and hotel, as well as broaden Monaker’s addressable market of B2B clients.
Exclusive access to key supplier contracts, including those for air, car, and hotel rentals, which will be accessed via the booking engine technology acquired from IDS.
The agreements are designed to acquire access to specialized, and in some cases unique, inventory for distribution through the company’s booking engine and nexttrip.biz.
A robust, cloud-based customer relationship management (CRM) platform to manage travel customer relationships and allow a more complete service offering.
Access to special merchant accounts that can support between $500,000 and $1 million per month in merchant processing capacity.
Mr. Kerby added that this important acquisition and stronger relationship with IDS was a “strategic extension” of the earlier engagement with IDS for the development of Monaker’s nexttrip.biz platform, which began last year.
Following the IDS technologies enhancement for nexttrip.biz, Monaker plans to commercially launch subscription-based, direct-to-consumer access to the site. For $19 per month or $150 per year, travelers worldwide will be able to gain access to wholesale-level pricing for all their travel needs, and create air, car, lodging - including vacation rentals -and tour packages, for additional savings.
About IDS Technology
IDS Technology is a software development company with nearly three decades of experience in the hospitality industry. As a leader in travel inventory aggregation and distribution, its Internet Distribution Systems empower more than 100 leading travel companies worldwide to stay competitive in the rapidly evolving travel industry. Its cloud-based travel software solutions help distributors and suppliers increase their revenue and boost efficiency through automated mapping technology, API connectivity, and profit optimization tools. Always at the forefront of travel technology development, its solutions perform across the entire distribution chain to support travel product suppliers, distributors and meta searches. For more information, visit www.ids.technology.
About Monaker Group
Monaker Group is a technology-driven travel company focused on delivering innovation to the alternative lodging rental (ALR) market. The Monaker Booking Engine (MBE) provides access to more than 2.6 million instantly bookable vacation rental homes, villas, chalets, apartments, condos, resort residences, and castles. MBE offers travel distributors and agencies an industry first: a customizable, instant-booking platform for alternative lodging. The company’s contracted travel partners include travel aggregators, consolidators, tour companies, airlines and more than 250,000 travel agents. For more about Monaker Group, visit?www.monakergroup.com.
Nexttrip.biz is customizable business travel booking and management solution for small and medium-sized businesses. Through a branded and customized website, business owners and employees can search for and securely access exclusive discounted pricing across air, hotel/ALR, car, and other ancillary travel services. Nexttrip.biz can be configured to an SMB’s particular travel policies, with bookings recorded for easy corporate expense tracking and reporting. For more information, visit www.nexttrip.biz.
Important Cautions Regarding Forward Looking Statements
This release includes “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements give our current expectations, opinions, belief or forecasts of future events and performance. A statement identified by the use of forward-looking words including “will,” “may,” “expects,” “projects,” “anticipates,” “plans,” “believes,” “estimate,” “should,” and certain of the other foregoing statements may be deemed forward-looking statements. Although Monaker believes that the expectations reflected in such forward-looking statements are reasonable, these statements involve risks and uncertainties that may cause actual future activities and results to be materially different from those suggested or described in this news release. All forward-looking statements are expressly qualified in their entirety by the “Risk Factors” and other cautionary statements included in Monaker’s annual, quarterly and special reports, proxy statements and other public filings with the Securities and Exchange Commission (“SEC”), including, but not limited to, the company’s Annual Report on Form 10-K (as amended) for the year ended February 28, 2019 and the company's subsequently filed Quarterly Reports on Form 10-Q, which have been and will be filed with the SEC and are/will be available at www.sec.gov. Investors are cautioned that any forward-looking statements are not guarantees of future performance and actual results or developments may differ materially from those projected. The forward-looking statements in this press release are made as of the date hereof. The company takes no obligation to update or correct its own forward-looking statements, except as required by law, or those prepared by third parties that are not paid for by the company.
Director of Corporate Development
Well, he's moved to bigger venues.
Hate to see the junk on the board now.
Should have just shut it down, imo. Preserve the integrity and reputation.
Transcript of AMRN CEO Thero presentation at JPM:
The transcript follows the text of slides[previous post] reasonably well.
AMRN: Presented Vascepa at JPM Health today, 12:30, CEO Thero:
https://tinyurl.com/y9shcxeh Dr. Bhatt
https://tinyurl.com/y7qp2yy3 Panel after AHA, November 10-12
Last link corresponds to slide deck at JPM
Many $$$ Billion market for Vascepa is forecast
I have been prescribed Vascepa, off label, since April 2013. I currently co-pay $9 for a 3-month supply
$NSPX .0041? SEE WHAT DOCTORS ARE SAYING ABOUT ITS DRUG. SHOULD BE NO LESS THAN 10 CENTS DO U TRADE TO MAKE MONEY??!!
$NSPX 0041?! SERIOUSLY?!https://t.co/1PKOV8DPxx??? ; ;
LIKE HOW CAN PEOPLE LOOK THIS GIFT HORSE in the mouth like this???!! NSME AN OTC STOCK YOU KNOW trading at 0046 on the ask with only 150 million A/S. Now add that it's a pharmaceutical. NAME A PHARMACEUTICAL OTC STOCK with 150 million O/S trading less than 2 cents anywhere. AM I THE ONLY TRADER WHO DOES A COMPARATIVE MARKET ANALYSIS OF stocks???!!
Some say it went dark. Yes NSPX went dark after they purchased Lewis and Clark Pharmaceuticals A PRIVATE cancer biotech company with state of the art labs. Yes they went dark and silent but DID YOU SEE THE MASSIVE NEWS they silently released LESS THAN 3 MONTHS AGO???!! DID YOU???!
$NSPX eligible $12 MILLION from Transaction. Not 12 cents, 12 dollars, TWELVE MILLION DOLLARS!!!! Like this is nuts
https://t.co/2iNhYy7KfE ; ;
LOOK AT NSPX BREAKTHROUGH DRUG THAT COULD REPLACE CHEMOTHERAPY. This was on the NEWS. Cancer research/cures dont happen over night and MISPARGARIN HAVE ALREADY CURED PATIENTS that everything else failed. .0046????! What???!! LOOK.
$ATLS 0069!!??? Was $7 three years ago, $50 before that. FORMER NASDAQ once did 400 million in SALES. Dont sleep on 0072 on the ask. BADLY OVERSOLD 52 week high 10 cents!! ATLS only this low because its unknown. Not for long!
ATLS ATLS ATLS ATLS ATLS ATLS ATLS ATLS ATLS ATLS ATLS ATLS ATLS ATLS ATLS ATLS ATLS ATLS ATLS ATLS ATLS ATLS ATLS ATLS ATLS ATLS ATLS ATLS ATLS ATLS ATLS ATLS ATLS ATLS ATLS ATLS ATLS ATLS ATLS ATLS ATLS ATLS ATLS ATLS ATLS ATLS ATLS ATLS ATLS
ACAD Sold 5000 $15 JAN19 PUT contracts and bought 5000 $27 Jan19 CALL contracts.
I admired it because the trade basically cost him nothing to put on by using the money he got paid on the PUTS he financed the cost of buying the calls. Of course this "Big Dog" obviously has the deep pockets necessary to satisfy the margin requirements of a trade this large.Re: JAN 2019 strike 27 vol.1.5 MILLION dollars risk at 1.80 vol. 7954
$BWMG New Dive system hits market,makes Kickstarter goal.
Yes! $40,965pledged of $40,000 goalKickStarter
69 backers 32 days to go
Not bad 30 hours and it made the goal, not bad at all. this is the smallest lightest dive system ever https://www.kickstarter.com/projects/diveblu3/nemo-by-blu3-the-worlds-smallest-dive-system?ref=discovery&term=nemo
$349 for whole product dive 1 hour+ to 10 feet with rechargeable battery.
It is BWMG product (Brownies)
The 6 packs are gone, so they raised price $300 for the 6 pack and made new a offer. If you read comments on KickStarter people are amazed at price.
BTW just who are buying 6 packs? Its dealers, scuba shops, they know a good deal when they see it, they will resell them.
If this goes viral, BWMG stock will go viral. Cool videos on the KS link above.
Thanks. Moved up then down and a giant move up today.
IZEA Awesome call bro.
Brief summary of today's news and SEC filings:
"About HTX-011 for Postoperative Pain
HTX-011, which utilizes Heron’s proprietary Biochronomer® drug delivery technology, is an investigational, long-acting, extended-release formulation of the local anesthetic bupivacaine in a fixed-dose combination with the anti-inflammatory meloxicam for the management of postoperative pain. By delivering sustained levels of both a potent anesthetic and a local anti-inflammatory agent directly to the site of tissue injury, HTX-011 was designed to deliver superior pain relief while reducing the need for systemically administered pain medications such as opioids, which carry the risk of harmful side effects, abuse and addiction. HTX-011 has been shown to reduce pain significantly better than placebo or bupivacaine alone in five diverse surgical models: hernia repair, abdominoplasty, bunionectomy, total knee arthroplasty and breast augmentation. HTX-011 was granted Fast Track designation from the FDA in the fourth quarter of 2017 and Breakthrough Therapy designation in the second quarter of 2018. In the second half of 2018, Heron expects to submit a New Drug Application (NDA) to the FDA for HTX-011."
CMG weekly room to 400 than 420-440 than 450-500
Chipotle Mexican Grill Q1 EPS $2.13 vs. $1.57 Est.; Q1 Revs. $1.15B vs. $1.15B Est
CMG has 15% shorts,
new former TacoBell ceo,
high cash flow,massive growth potential
no BWLD premium built in.. squeeze is on...
2018 reversal year
restaurants to benefit more than avg from tax plan
3. 7 million shorts
Monaker to Present at the 30th Annual ROTH Conference on March 13, 2018
WESTON, FL – March 1, 2018 – Monaker Group (NASDAQ: MKGI), a travel and technology company focused on the alternative lodging rental (ALR) market, has been invited to present at 30th Annual Roth Conference being held on March 11-13, 2018 at The Ritz-Carlton in Dana Point, California.
Monaker CEO Bill Kerby is scheduled to present on Tuesday, March 13 at 2:30 p.m. Pacific time. He will be joined by the company’s director of corporate development, Richard Marshall, for one-on-one meetings with institutional analysts and investors held at the conference.
Management will discuss the Monaker Booking Engine (MBE), the first customizable, alternative lodging reservation system with instant booking of vacation homes, villas, chalets, apartments, condos and castles.
The presentation will be also webcast live and available for replay here and via the investor relations section of the company’s website at monakergroup.com.
This year’s Roth Conference will feature presentations from hundreds of growth companies, along with Q&A sessions, expert panels, and thousands of one-on-one and small group meetings. As one of the largest of its kind, the event is designed to provide investors with a unique opportunity to gain insight into emerging growth companies across a variety of industry sectors.
For more information about the conference or to schedule a one-on-one meeting with Monaker, please contact your Roth representative at (800) 678-9147 or via e-mail at firstname.lastname@example.org.
About Roth Capital Partners
ROTH Capital Partners, LLC is a relationship-driven investment bank focused on serving emerging growth companies and their investors. As a full-service investment bank, ROTH provides capital raising, M&A advisory, analytical research, trading, market-making services and corporate access. Headquartered in Newport Beach, CA, ROTH is privately-held and employee owned, and maintains offices throughout the U.S. For more information on ROTH, please visit www.roth.com.
About Monaker Group
Monaker Group is a technology-driven travel company focused on delivering innovation to alternative lodging rentals (ALR) market. The Monaker Booking Engine (MBE) delivers instant booking of more than one million vacation rental homes, villas, chalets, apartments, condos, resort residences and castles. MBE offers travel distributors and agencies an industry-first: a customizable, instant-booking platform for alternative lodging. For more information, visit www.monakergroup.com.
Important Cautions Regarding Forward Looking Statements
This press release contains forward-looking statements that involve risks and uncertainties concerning the plans and expectations of Monaker. These statements are only predictions and actual events or results may differ materially from those described in this press release due to a number of risks and uncertainties, some of which are out of our control. The potential risks and uncertainties include, among others, the expectations of future growth may not be realized. These forward-looking statements are made only as of the date hereof, and Monaker undertakes no obligation to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise. All forward-looking statements are expressly qualified in their entirety by the “Risk Factors” and other cautionary statements included in Monaker’s annual, quarterly and special reports, proxy statements and other public filings with the Securities and Exchange Commission (“SEC”), including, but not limited to, the company’s Annual Report on Form 10-K for the period ended February 28, 2017, which has been filed with the SEC and is available at www.sec.gov.
Director of Corporate Development
VRX Valeant news out: Valeant Pharmaceuticals International Inc. (VRX.T) announced that it had secured a licensing agreement for a potential psoriasis drug Tuesday afternoon, just hours before the company is scheduled to announce quarterly earnings. Valeant said it reached an exclusive agreement with Kaken Pharmaceutical Co. Ltd. for KP-470 to develop and commercialize topical products with the compound in the U.S., Canada and Europe. "Medical dermatology remains a key therapeutic area of focus for the Company, and we are dedicated to developing new treatment options," Valeant Chief Executive Joseph Papa said in Tuesday's announcement (http://ir.valeant.com/news-releases/2018/02-27-2018-234521731). Valeant shares gained about 1.8% in after-hours trading Tuesday as investors awaited the company's fourth-quarter earnings report, scheduled to be released Wednesday morning before markets open.